Glaxo to double China R&D

GlaxoSmithKline is making ambitious plans to expand its R&D operations in China. According to Glaxo's Carol Zhu, who runs the operation, the company will more than double the number of researchers it has on staff in China. The R&D arm will grow from a staff of 170 today to 200 by year's end and plans to reach 350 next year. The pharma giant then plans to hold staffing at that level for several years before adding new researchers. GSK report

Suggested Articles

LianBio aims to bring much-needed new drugs to China and serve as a partner for U.S. biotechs looking to expand into Asia.

Despite the setback, Fulcrum hailed the data as “very encouraging,” zeroing in on results from a pre-specified sensitivity analysis to make its case.

Bayer has struck a $425 million upfront deal to buy KaNDy in the belief its treatment for menopause-related hot flashes has blockbuster potential.